KNOWLEDGE BANK

Interviews

Takeda Pharmaceutical Company Limited

Chief Medical & Scientific Officer
Scientific progress depends upon collaboration iPS cell technology is at the forefront of pharmaceutical innovation and Takeda strives to bring innovative treatments to patients Both Takeda and CiRA have the common goal of providing patients and healthcare professionals with innovative new treatments

Articles

Pharma Regulatory Bottlenecks and Vaccination Delays

The world is grappling with the inefficiencies that have plagued the healthcare system since covid has wreaked havoc The unprecedented loss of human lives could have been prevented if vaccine diplomacy was robust and supported by more affluent nations Half of the inefficiencies and disparities that plague the healthcare and pharma sector

Research Insights

Challenges Of Glycosylation Analysis And Control: An Integrated Approach To Producing Optimal And Consistent Therapeutic Drugs

Abstract Glycosylation of therapeutic proteins has a profound impact on their safety and efficacy Many factors shape the glycosylation of biotherapeutics ranging from expression systems and cell culture processes to downstream purification strategies Various analytical technologies have been developed to address questions concerning different aspects of glyc

Case Studies

Impact Of Substitution Among Generic Drugs On Persistence And Adherence:a Retrospective Claims Data Case Study

Abstract Once the period of exclusivity on a reference medicine expires it is possible to apply for marketing of a generic version of that medicine By definition a generic product is considered interchangeable with the innovator brand product when it demonstrates the same qualitative and quantitative composition in active substances the same pharmaceutical form and bi...

Techno Trends

Moderna and Merck Developed Novel mRNA-4157/V940, Personalised mRNA Cancer Vaccine

Moderna and Merck developed mRNAV an investigational personalised mRNA cancer vaccine in combination with KEYTRUDA pembrolizumab for the treatment of highrisk melanoma following complete resection The combination of mRNAV with KEYTRUDA demonstrated efficacy

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Kinase Inhibitors as Antiviral Agents

Thanigaimalai Pillaiyar

Thanigaimalai Pillaiyar is working as an independent junior research group leader and establishing a research group at the Tübingen Center for Academic Drug Discovery (TüCAD2), University of Tübingen. His research interests include medicinal chemistry of orphan G protein-coupled receptors (GPCRs), synthetic organic chemistry, and dual SARS-CoV-2 Mpro-kinase inhibitors.

 

Stefan Laufer

Stefan Laufer is Professor for Pharmaceutical/Medicinal Chemistry at Tuebingen University and chairs the TüCAD2. His research interests are anti inflammatory and cancer drug discovery. He authored more than 500 publications, 15 books/book chapters and is inventor in 42 patent families with >330 national applications. 4 compounds from his lab made it to first into man studies.

 

2

Approach for Producing Pharmaceuticals in Layer By Layer Fashion: Additive Manufacturing

Lakshmi usha Ayalasomayajula

Lakshmi usha Ayalasomayajula is an Assistant Professor in the Department of Pharmaceutical Technology at M.R. College of Pharmacy, India with 9 years of teaching and research experience. She has published 30 papers in international and national journals and has presented 20 papers in various conferences as author and co-author.

 

Earle Radha Rani

Earle Radha Rani is working as assistant professor in department of pharmaceutical technology, Maharajah’s College of Pharmacy, Andhra Pradesh, India. She has 7 years of teaching experience and has published over 30 research and review articles in several reputed national and international journals. Her areas of interest include novel drug delivery systems.

 

AVS Ksheera Bhavani

AVS Ksheera Bhavani is working as assistant professor in department of Pharmaceutical Biotechnology, Maharajah’s College of Pharmacy, Andhra Pradesh, India. She has about 10 years of teaching experience and has published over 10 research and review articles in several reputed national and international journals. Her areas of interest include novel drug delivery systems.

 

Kishore Pathivada

kishore pathivada ,an under graduate from Maharajah's college of pharmacy, Vizianagaram, during the year, 2017-21. I Qualified GPAT-2021 with AIR 705 and I also got qualified in NIPER JEE-2021 with AIR 62.Currently Iam pursuing my master's degree in Dept. of pharmaceutical Analysis at NIPER Mohali, Punjab which is one of the top most reputed colleges in INDIA in the field of Pharmaceutical Sciences and Research.

 

3

Syringe-like Bacterial Nanomachine Emerges as Potential Therapeutics Delivery Device

Chanchal Kumawat

I am Chanchal Kumawat. I started my journey in science as Ph.D. student at Regional Centre for Biotechnology and continued as postdoctoral fellow at Max Perutz labs, Austria.  I enjoyed making scientific discoveries in the laboratory and now, enjoy communicating it as a science writer.

 

4

Nanotechnology as a Potential Therapeutic Strategy in Breast Cancer Management

Mr. Rahul Pal

Mr. Rahul Pal (Young Scientist), Ass. Prof. Department of Pharmacy, Jagannath University, Jaipur, holds B. Pharm, M. Pharm (Pharmaceutics), and PhD* at Chitkara University. He has authored 50+ publications, 8 textbooks, 12 edited book, secured 38 patents, 3 copyrights, received the Young Researcher Award (2025), and actively contributes as reviewer, editor, and speaker in national and international academic forums.

5

Boosting NICU Safety

Norhan Attia

Norhan Attia, clinical pharmacist with five years' experience at Assiut University Hospital, Egypt, specialising in Neonatal Intensive Care. Expert in medication reviews, IV admixtures, and optimising pharmacotherapy outcomes. Currently a dedicated teaching assistant, focusing on pharmaceutical education and enhancing medication safety in NICU settings.

press releasesRead more...

Global Experts to Gather in Osaka for PDA Aseptic Manufacturing and Regulatory Science Symposium 2026

As pharmaceutical manufacturers worldwide continue to navigate the implementation of PICS GMP Annex a landmark international symposium in Japan will bring together regulators industry leaders

Researchers Gain Faster Access to Complex DNA as Integrated DNA Technologies and Ansa Biotechnologies Expand Ordering Platform

Integrated DNA Technologies IDT a Danaher company and a global leader in genomics and Ansa Biotechnologies Inc a trusted partner for DNA synthesis today announced an expansion of their partnership

Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience

Biocytogen Pharmaceuticals Beijing Co Ltd Biocytogen SSE HKEX today announced that it has entered into a nonexclusive licensing agreement with Qilu Pharmaceutical Co Ltd

Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates

Heidelberg Pharma AG FSE HPHA a clinicalstage biotech company developing innovative Antibody Drug Conjugates ADCs today announced that its whollyowned subsidiary Heidelberg Pharma Research

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China

Eisai Co Ltd and Biogen Inc Nasdaq BIIB announced today that the National Medical Products Administration NMPA of China has approved the subcutaneous formulation subcutaneous autoinjector SCAI

Roche’s Vabysmo demonstrates sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration (nAMD)

Roche announced today new twoyear data from the Phase IIIbIV SALWEEN study of Vabysmo faricimab presented at the th AsiaPacific Vitreoretina Society APVRS Congress in Australia

EventsRead more...

03 - 05

Sep 2026

5th MENA Congress for Rare Diseases 2026

Beach Rotana Hotel, Abu Dhabi,...

14 - 15

Sep 2026

16th American DDF Summit

Omni Boston Hotel at the Seapo...

15 - 17

Sep 2026

COPD Drug Development Summit 2026

Street, Boston, MA 02210, USA

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

28 - 01

Sep 2026

LATEST NEWSRead more...

Global Experts to Gather in Osaka for PDA Aseptic Manufacturing and Regulatory Science Symposium 2026

As pharmaceutical manufacturers worldwide continue to navigate the implementation of PICS GMP Annex a landmark international symposium in Japan will bring together regulators industry leaders

HUTCHMED Enters into Agreement with GSK for Novel KRAS-EGFR Cancer Therapy

HUTCHMED has entered into an exclusive development and licensing agreement with GSK for HMPLA an investigational antibodytargeted therapy conjugate ATTC designed to target KRAS and EGFR in solid tumours

Everest Medicines Receives Approval for CARDAMYST to Treat Acute PSVT

Everest Medicines has received approval from Chinas National Medical Products Administration NMPA for CARDAMYST etripamil nasal spray for the conversion of acute symptomatic episodes

HUTCHMED Announces Approval of ATLED® (Fanregratinib) for FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

HUTCHMED has received conditional approval from Chinas National Medical Products Administration NMPA for ATLED fanregratinib to treat adults with advanced metastatic or unresectable intrahepatic cholangiocarcinoma ICC with FGFR fusion or rearrangement who have previously received systemic therapy

Osivax Enters into Collaboration with GC Biopharma to Develop Next-Generation Influenza Vaccine

Osivax and GC Biopharma have entered into a strategic collaboration to develop and commercialise a nextgeneration seasonal influenza vaccine designed to provide broader and more durable protection against a range of influenza strains

Cipla Enters into Agreement with SBP Group for HER2 bispecific ADC TQB2102

Cipla and Sino Biopharmaceutical SBP Group have entered into an exclusive licensing and supply agreement for Rolditamig Deuderuxtecan also known as TQB a HERtargeted bispecific antibodydrug conjugate ADC being developed for the treatment of cancer